The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

OBJECTIVE: To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Headache
Huvudupphovsmän: Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Research Submissions
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7590156/
https://ncbi.nlm.nih.gov/pubmed/32851644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13929
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk